trial
as of 2026-07-01Using Speech to Monitor Symptom Severity in Arabic Speaking Patients With Schizophrenia
NCTId NCT05563818
at a glance
Phase — · Completed
Enrollment 57 (actual)
Sponsored by Hikma Pharmaceuticals LLC
Primary completion 2022-12-20
Synthesized from structured facts only — each point cited above.
Design & status
Phase
—
Status
Completed
Enrollment
57 (actual)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2021-11-09
Primary completion
2022-12-20
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
Hikma Pharmaceuticals LLCLead Sponsor
Winterlight LabsCollaborator
Sites
4 total
Algiers, AlgeriaCairo, EgyptAmman, JordanJeddah, Saudi Arabia
Facts & assertions
4 sourced
Enrollment
57
Phase
NA
Primary Completion Date
2022-12-20
Status
COMPLETED
relationships
The graph out of here
lead_sponsor
company
collaborator
company
indication